Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 1, 2016

View Archived Issues

European orphan drug designation for fimaporfin to treat cholangiocarcinoma

Good Doctor Pharmaceutical Group reports new PDE inhibitors

Oncocure Biotechnology patents CRM1 inhibitors

Glenmark Pharmaceuticals discloses ADH5 inhibitors

Constellation Pharmaceuticals describes EZH2 inhibitors

PsychoGenics and Sunovion Pharmaceuticals develop antidepressants

Daewoong Pharmaceutical announces Nav1.7 sodium channel blockers

Latanoprost-eluting contact lenses demonstrate IOP-lowering effects in vivo

Betagenon and Baltic Bio start phase IIa trial of O-304

Kleo licenses IP rights from Yale, completes Series A funding

Scientists identify novel disease-causing mutations in DSP gene

European Commission approves Pfizer's crizotinib for ROS-1 positive NSCLC

Novartis presents new tetrahydroisoquinoline with good oral bioavailability in vivo

Mallinckrodt completes Stratatech acquisition

Forma Therapeutics meets development milestone in collaboration with Celgene

Aptahem reports on anticoagulant effect of APTA-1 in animal studies

Facio establishes tool to aid in FSHD drug discovery

AbbVie reports development of selective BET family bromodomain inhibitors

Neurocrine submits NDA for valbenazine in the treatment of tardive dyskinesia

SK Chemicals launches SKYCellflu Quadrivalent influenza vaccine in South Korea

MK-8449: a second generation SYK/ZAP70 inhibitor from Merck

FDA awards Santhera USD 246,000 for the development of omigapil

Intramyocardial AdVEGF-DdNdC gene therapy shows potential in patients with refractory angina

Santen and Kerui establish ophthalmic joint venture in China

NIAID grant supports Sedia's development of HIV test for recent infections

Expected efficacy not observed in Japanese phase II/III study of HP-3150 for cancer pain

FDA grants orphan drug designation to nivolumab for the treatment of esophageal cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...